Instil Bio (TIL) AI Stock Analysis

• Market Cap: $95.34M
• Dividend Yield: N/A
• Average Volume (3M): 83.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 5.92
• Revenue Growth: N/A
• EPS Growth: 52.54%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): -11.39
• Shares Outstanding: 6,525,887
• 10 Day Avg. Volume: 74,984
• 30 Day Avg. Volume: 83,015
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 27.36
• Price to Cash Flow (P/CF): -2.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $81.00
• Price Target Upside: 454.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Instil Bio is facing substantial financial and operational challenges, primarily due to its inability to generate revenue and persistent losses. While technical analysis shows a bearish trend, there might be a short-term support. The recent loan acquisition could improve financial stability, but overall, the company's stock remains risky, reflected in its low valuation score.

Positive Factors

Clinical Trials

The SYN-2510 1L NSCLC chemo combo trial has begun dosing with plans to escalate and enroll around 60 patients by the end of the year, indicating progress in clinical trials.

Financial Stability

Instil Bio is sufficiently capitalized with $112.5MM through upcoming key milestones, which supports its financial stability.

Milestone Payment

Instil Bio is expected to submit an IND for SYN-2510 in the U.S., potentially triggering a $10MM milestone payment.

Negative Factors

Competitive Pressure

Instil appears to be losing ground to multiple new assets that are expected to submit INDs by YE25.

Delayed U.S. Trials

For the second time, Instil has pushed out the initiation of the U.S. trial evaluating AXN-2510 in combo with chemo as a treatment for 1L NSCLC to YE25.

Valuation Concerns

Recent acquisitions by major companies highlight a valuation gap for Instil, suggesting it is undervalued.

Instil Bio Business Overview & Revenue Model

Company Description

Instil Bio is a biotechnology company focused on developing innovative cancer therapies. Specializing in tumor-infiltrating lymphocyte (TIL) technology, Instil Bio is dedicated to advancing cell therapy treatments that harness the power of the immune system to combat solid tumors. The company operates in the biopharmaceutical sector, aiming to provide novel therapeutic options for patients with unmet medical needs in oncology.

How the Company Makes Money

Instil Bio generates revenue primarily through the development and commercialization of its TIL-based therapies. The company may enter into strategic partnerships and collaborations with other biotech firms, research institutions, or pharmaceutical companies to co-develop and commercialize therapies, which can include upfront payments, milestone payments, and royalties based on sales. Additionally, as its products move through clinical trials and, if successful, receive regulatory approval, revenue can be generated from the sale of these therapies to healthcare providers and institutions treating cancer patients. Other potential revenue streams could include licensing its technology to other companies in the biotechnology and pharmaceutical sectors.

Instil Bio Financial Statement Overview

Summary

Instil Bio is facing significant financial challenges, characterized by no revenue generation, ongoing losses, and negative cash flows. While the balance sheet shows liquidity strength, the reliance on equity financing poses dilution risks. The company's financial health is precarious, requiring substantial strategic shifts to achieve sustainable operations.

Income Statement

Instil Bio has reported no revenue for several consecutive years, indicating significant challenges in monetizing its technology or products. The absence of revenue coupled with consistent and substantial net losses highlight severe profitability issues. Although there is a reduction in net loss from the prior year, the company still faces major financial hurdles.

Balance Sheet

The company maintains a reasonable cash position with cash and short-term investments of $113 million, providing some liquidity. However, the debt-to-equity ratio is low due to minimal debt, which is a positive. The equity ratio indicates a strong reliance on equity financing, suggesting potential dilution risks for investors. Overall, the balance sheet shows liquidity strength but significant equity erosion over time.

Cash Flow

Operating cash flow remains deeply negative, reflecting ongoing operational losses. There is a notable decrease in negative free cash flow from the previous year, indicating some improvement in cash management. However, consistent negative cash flow from operations poses a significant risk to financial sustainability without additional financing.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	138.00K
	Gross Profit
0.00	-4.76M	-5.99M	-2.75M	138.00K
	EBIT
-73.54M	-90.54M	-226.46M	-155.56M	-33.64M
	EBITDA
-62.53M	-146.12M	-217.38M	-154.00M	-33.39M
	Net Income Common Stockholders
-74.14M	-156.09M	-223.18M	-156.79M	-37.74M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
113.31M	150.36M	260.92M	454.10M	241.71M
	Total Assets
263.57M	325.63M	482.13M	609.98M	319.01M
	Total Debt
1.02M	86.05M	79.90M	0.00	0.00
	Net Debt
-7.79M	76.86M	36.19M	-37.59M	-241.71M
	Total Liabilities
94.13M	99.80M	118.52M	54.78M	358.61M
	Stockholders Equity
169.44M	225.83M	363.61M	555.20M	-39.60M
Cash Flow		Free Cash Flow
-55.70M	-102.69M	-264.75M	-179.97M	-80.43M
	Operating Cash Flow
-55.70M	-82.03M	-180.16M	-122.14M	-29.62M
	Investing Cash Flow
53.97M	41.13M	114.54M	-474.40M	-51.12M
	Financing Cash Flow
1.75M	8.08M	71.89M	393.16M	313.05M

Instil Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.61
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Negative. The current price of 14.61 is below the 20-day moving average (MA) of 18.41, below the 50-day MA of 20.34, and below the 200-day MA of 24.25, indicating a bearish trend. The MACD of -0.72 indicates Positive momentum. The RSI at 41.90 is Neutral, neither overbought nor oversold. The STOCH value of 8.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIL.

Instil Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
IOVA	48 Neutral	$983.63M	―	-57.48%	―	13698.99%	31.46%
ADAP	46 Neutral	$66.06M	―	-273.36%	―	194.23%	45.50%
CRSP	46 Neutral	$2.81B	―	-19.20%	―	-89.95%	-123.71%
FATE	42 Neutral	$86.28M	―	-54.21%	―	-78.55%	-0.92%
BLUE	36 Underperform	$48.46M	―	-295.35%	―	184.12%	31.92%
TIL	30 Underperform	$95.34M	―	-37.51%	―	―	52.54%

Instil Bio Corporate Events

Instil Bio Reports 2024 Financial Results and Outlook

Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.